WO2001056590A3 - Verwendung von proteinkinase-inhibitor-alpha - Google Patents

Verwendung von proteinkinase-inhibitor-alpha Download PDF

Info

Publication number
WO2001056590A3
WO2001056590A3 PCT/EP2001/001002 EP0101002W WO0156590A3 WO 2001056590 A3 WO2001056590 A3 WO 2001056590A3 EP 0101002 W EP0101002 W EP 0101002W WO 0156590 A3 WO0156590 A3 WO 0156590A3
Authority
WO
WIPO (PCT)
Prior art keywords
utilization
protein kinase
kinase inhibitor
alpha
inhibitor alpha
Prior art date
Application number
PCT/EP2001/001002
Other languages
English (en)
French (fr)
Other versions
WO2001056590A2 (de
Inventor
Ralph Knoell
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Priority to JP2001556489A priority Critical patent/JP2003531114A/ja
Priority to EP01905712A priority patent/EP1253931A2/de
Priority to AU2001233723A priority patent/AU2001233723A1/en
Publication of WO2001056590A2 publication Critical patent/WO2001056590A2/de
Publication of WO2001056590A3 publication Critical patent/WO2001056590A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)

Abstract

Die vorliegende Erfindung betrifft in einem Aspekt die Verwendung von PKI-alpha und/oder dessen Derivate zur Blutdrucksenkung, als beta-Antagonisten und zur Herstellung eines Medikaments für die Prävention und/oder Behandlung von Krankheiten, bei denen ein beta-Antagonist verwendet werden kann. In einem weiteren Aspekt betrifft die Erfindung die Verwendung eines Inhibitors von PKI-alpha oder eines Derivates davon zur Blutdruckerhöhung, als beta-Agonist und zur Herstellung eines Medikaments für die Behandlung und/oder Prävention von Krankheiten, bei denen ein beta-Agonist verwendet werden kann.
PCT/EP2001/001002 2000-02-03 2001-01-31 Verwendung von proteinkinase-inhibitor-alpha WO2001056590A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2001556489A JP2003531114A (ja) 2000-02-03 2001-01-31 プロテインキナーゼα阻害剤の使用
EP01905712A EP1253931A2 (de) 2000-02-03 2001-01-31 Verwendung von proteinkinase-inhibitor-alpha
AU2001233723A AU2001233723A1 (en) 2000-02-03 2001-01-31 Utilization of protein kinase inhibitor alpha

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10004858.7 2000-02-03
DE10004858A DE10004858A1 (de) 2000-02-03 2000-02-03 Verwendung von Proteinkinase-Inhibitor-alpha

Publications (2)

Publication Number Publication Date
WO2001056590A2 WO2001056590A2 (de) 2001-08-09
WO2001056590A3 true WO2001056590A3 (de) 2002-06-20

Family

ID=7629772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/001002 WO2001056590A2 (de) 2000-02-03 2001-01-31 Verwendung von proteinkinase-inhibitor-alpha

Country Status (5)

Country Link
EP (1) EP1253931A2 (de)
JP (1) JP2003531114A (de)
AU (1) AU2001233723A1 (de)
DE (1) DE10004858A1 (de)
WO (1) WO2001056590A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
CA2659364C (en) * 2006-08-01 2017-08-22 Board Of Regents Of The University Of Texas System Identification of a micro-rna that activates expression of .beta.-myosin heavy chain
US9974759B2 (en) 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022122A1 (en) * 1996-11-21 1998-05-28 Promega Corporation Alkyl peptide amides and applications
WO1998044349A1 (en) * 1997-04-03 1998-10-08 University Technology Corporation Method for identifying adrenergic receptor antagonists having good tolerability
US5846720A (en) * 1989-07-18 1998-12-08 Oncogene Science, Inc. Methods of determining chemicals that modulate expression of genes associated with cardiovascular disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846720A (en) * 1989-07-18 1998-12-08 Oncogene Science, Inc. Methods of determining chemicals that modulate expression of genes associated with cardiovascular disease
WO1998022122A1 (en) * 1996-11-21 1998-05-28 Promega Corporation Alkyl peptide amides and applications
WO1998044349A1 (en) * 1997-04-03 1998-10-08 University Technology Corporation Method for identifying adrenergic receptor antagonists having good tolerability

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FRANCIOSA J A: "BETA-ADRENERGIC BLOCKING AGENTS: PAST, PRESENT, AND FUTURE PERSPECTIVES", CORONARY ARTERY DISEASE, CURRENT SCIENCE LTD, XX, vol. 10, no. 6, September 1999 (1999-09-01), pages 369 - 376, XP001000657, ISSN: 0954-6928 *
KNOELL, R. (1) ET AL: "The protein kinase inhibitor - alpha gene: Another key to postischaemic myocardial dysfunction.", EUROPEAN HEART JOURNAL, (AUG., 1999) VOL. 20, NO. ABSTR. SUPPL., PP. 315. MEETING INFO.: XXIST CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY BARCELONA, SPAIN AUGUST 28-SEPTEMBER 1, 1999 EUROPEAN SOCIETY OF CARDIOLOGY., XP000999001 *
MARULLO S ET AL: "EXPRESSION OF HUMAN BETA-1 AND BETA-2 ADRENERGIC RECEPTORS IN ESCHERICHIA-COLI AS A NEW TOOL FOR LIGAND SCREENING", BIO-TECHNOLOGY (NEW YORK), vol. 7, no. 9, 1989, pages 923 - 927, XP001018679, ISSN: 0733-222X *
MITCHELL R D ET AL: "Heat-stable inhibitor protein derived peptide substrate analogs: phosphorylation by cAMP-dependent and cGMP-dependent protein kinases.", BIOCHEMISTRY, (1995 JAN 17) 34 (2) 528-34., XP001021452 *
VAN PATTEN S M ET AL: "The alpha- and beta-isoforms of the inhibitor protein of the 3',5'-cyclic adenosine monophosphate-dependent protein kinase: characteristics and tissue- and developmental-specific expression.", MOLECULAR ENDOCRINOLOGY, (1992 DEC) 6 (12) 2114-22., XP001021716 *

Also Published As

Publication number Publication date
WO2001056590A2 (de) 2001-08-09
JP2003531114A (ja) 2003-10-21
AU2001233723A1 (en) 2001-08-14
EP1253931A2 (de) 2002-11-06
DE10004858A1 (de) 2001-08-16

Similar Documents

Publication Publication Date Title
EP1485381B8 (de) Azolylaminoazine als inhibitoren von proteinkinasen
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
PL1687305T3 (pl) Pochodne 1H-imidazochinolin jako inhibitory kinaz białkowych
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
MXPA02005844A (es) Inhibidores de cinasas de proteina.
IL175568A (en) Tyrosine kinase inhibitors, containing them containing herbal remedies and their use in the preparation of a drug for the treatment of diseases
HUP0303363A2 (hu) Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
WO2004054581A3 (en) Cyclohexyl compounds as ccr5 antagonists
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
WO2004055010A3 (en) Cyclopropyl compounds as ccr5 antagonists
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2005056547A3 (en) Quinoxalines useful as inhibitors of protein kinases
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
ME00549B (me) Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja
WO2003051838A3 (en) Protein kinase inhibitors
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
WO2001056590A3 (de) Verwendung von proteinkinase-inhibitor-alpha
AU2002365288A1 (en) Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
MXPA04001205A (es) Compuesto para eliminar y/o mitigar la anhedonia.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001905712

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 556489

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001905712

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001905712

Country of ref document: EP